指南与共识眼底病与葡萄膜炎

重新审视羟氯喹剂量与视网膜病变筛查指南

Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.
指南 / 共识 · Am J Ophthalmol · 2020-06-28

本文通过文献综述探讨修订羟氯喹(HCQ)剂量与筛查指南的依据,指出美国眼科学会(AAO)三版指南均无处方医生参与制定,可能影响依从性。随着辅助检查进步,无症状HCQ视网膜病变(HCQR)更早检出,报告患病率升高且安全剂量上限下降,对处方者和患者构成更严格限制。建议重新考虑在HCQR最早迹象时停药,早期病例可减量并加强监测,并呼吁眼科医生与处方医生合作开展前瞻性研究。

要点

  • AAO三版HCQ剂量与HCQR筛查指南制定时均未纳入处方医生,可能降低依从性。
  • 辅助检查进步使无症状HCQR更早检出,报告患病率升高且安全剂量上限下降。
  • 早期HCQR可考虑减量并加强监测,而非立即停药,以平衡风险与获益。

核心结论

  • HCQ剂量与筛查指南应更新,并应由眼科医生与处方医生共同努力启动HCQ剂量与HCQR的前瞻性研究。

研究设计与样本

  • 本文为文献综述,通过PubMed检索HCQ剂量与HCQR筛查研究并进行选择性英文文献回顾。

主要发现

  • AAO已发布三版HCQ剂量与HCQR筛查指南,但写作委员会均未包括处方医生。
  • 辅助检查改善使无症状HCQR更早检出,导致报告患病率升高且安全剂量上限下降。
  • 这些趋势对处方者及患者构成更严格限制,部分患者可能在既往认为低于高风险阈值的剂量下已良好控制自身免疫病。

关键数值与推荐

  • 原文未报告具体剂量阈值、筛查间隔或诊断标准数值。

临床怎么用

  • 对早期HCQR病例,可考虑减量并加强视网膜病变监测,而非在最早迹象时立即停药。
  • 未来指南制定应纳入处方医生,并开展标准化收集数据、HCQ血药浓度、辅助检查集中判读的前瞻性研究。

局限性

  • 本文为文献综述,未提供原始研究数据或定量证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the rationale for revising the hydroxychloroquine (HCQ) dosing and screening guidelines and to identify the barriers to more effective guidelines in the future. DESIGN: Literature review. METHODS: A PubMed query of studies on HCQ dosing and HCQ retinopathy (HCQR) screening was conducted with a selective review of the English language literature. RESULTS: Three iterations of the American Academy of Ophthalmology HCQ dosing and HCQR screening guidelines have been published without including prescribing physicians on the writing committees. This may contribute to prescribing physicians' low adherence to the guidelines. As ancillary tests have improved, asymptomatic HCQR is being detected earlier, leading to a higher reported prevalence of HCQR and a drop in the ceiling for safe dosing. These trends put stricter constraints on prescribers and their patients, who may have had well-controlled autoimmune disease on HCQ doses that were previously considered to be below the high-risk threshold for HCQR. Indeed, stopping HCQ at the earliest sign of HCQR should be reconsidered; for cases of early HCQR, dose reduction and more intensive monitoring for retinopathy may strike a more appropriate balance between HCQ risk and benefits. A prospective study using the Diabetic Retinopathy Clinical Research Retina Network with standardized collection of data, HCQ blood levels, centralized grading of ancillary tests, and community and academic ophthalmologists would provide a stronger evidence base for future HCQ guidelines. CONCLUSIONS: The HCQ dosing and screening guidelines should be updated and a prospective study of HCQ dosing and HCQR should be initiated with the joint efforts of ophthalmologists and prescribing physicians.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Browning DJ, Yokogawa N, Greenberg PB, et al. Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. Am J Ophthalmol. 2020. PMID: 32610049. doi:10.1016/j.ajo.2020.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。